Cargando…
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994214/ https://www.ncbi.nlm.nih.gov/pubmed/33723793 http://dx.doi.org/10.1007/s11095-021-02994-1 |
_version_ | 1783669706713989120 |
---|---|
author | Busse, David Schaeftlein, André Solms, Alexander Ilia, Luis Michelet, Robin Zeitlinger, Markus Huisinga, Wilhelm Kloft, Charlotte |
author_facet | Busse, David Schaeftlein, André Solms, Alexander Ilia, Luis Michelet, Robin Zeitlinger, Markus Huisinga, Wilhelm Kloft, Charlotte |
author_sort | Busse, David |
collection | PubMed |
description | PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUC(ISF) estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%–143%CV(PK), integral-CA = 26.4%–72.6%CV(PK)) from recovery-related variability only in integral-CA (41.0%–50.3%CV(recovery)). This also led to increased variability of AUC(plasma) for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-021-02994-1. |
format | Online Article Text |
id | pubmed-7994214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-79942142021-04-16 Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin Busse, David Schaeftlein, André Solms, Alexander Ilia, Luis Michelet, Robin Zeitlinger, Markus Huisinga, Wilhelm Kloft, Charlotte Pharm Res Research Paper PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUC(ISF) estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%–143%CV(PK), integral-CA = 26.4%–72.6%CV(PK)) from recovery-related variability only in integral-CA (41.0%–50.3%CV(recovery)). This also led to increased variability of AUC(plasma) for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-021-02994-1. Springer US 2021-03-15 2021 /pmc/articles/PMC7994214/ /pubmed/33723793 http://dx.doi.org/10.1007/s11095-021-02994-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Paper Busse, David Schaeftlein, André Solms, Alexander Ilia, Luis Michelet, Robin Zeitlinger, Markus Huisinga, Wilhelm Kloft, Charlotte Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin |
title | Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin |
title_full | Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin |
title_fullStr | Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin |
title_full_unstemmed | Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin |
title_short | Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin |
title_sort | which analysis approach is adequate to leverage clinical microdialysis data? a quantitative comparison to investigate exposure and response exemplified by levofloxacin |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994214/ https://www.ncbi.nlm.nih.gov/pubmed/33723793 http://dx.doi.org/10.1007/s11095-021-02994-1 |
work_keys_str_mv | AT bussedavid whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT schaeftleinandre whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT solmsalexander whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT ilialuis whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT micheletrobin whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT zeitlingermarkus whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT huisingawilhelm whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin AT kloftcharlotte whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin |